Susquehanna International Group, LLP Satsuma Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.61 - $5.06 $25,845 - $214,387	42,369 Added 351.61%	54,419 $48,000
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $50,489 - $95,797	12,050 New	12,050 $72,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $211,704 - $351,477	-81,739 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.78 - $5.32 $53,929 - $75,900	-14,267 Reduced 14.86%	81,739 $311,000
Q4 2021 Feb 14, 2022	BUY	$4.15 - $6.24 $160,899 - $241,931	38,771 Added 67.74%	96,006 $432,000
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $140,481 - $221,861	30,943 Added 117.69%	57,235 $267,000
Q2 2021 Aug 11, 2021	BUY	$4.8 - $7.25 $126,201 - $190,617	26,292 New	26,292 $185,000
Q3 2020 Nov 16, 2020	SELL	$3.85 - $28.47 $29,452 - $217,795	-7,650 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $122,476 - $265,378	7,650 New	7,650 $220,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.